Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
Wolverine Stack Storage & Stability Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-WOLV-001
Version: 1.0
Effective Date: 10 December 2025
Product: Wolverine Stack Research Blend (BPC-157 + TB-500)
⚠️ Notice: Dual-component RUO kit. Components supplied separately. No pre-mixing permitted.
1. Product Overview
| Parameter | Specification |
| INN (Proposed) | Wolverine Stack Research Blend (Protocol Name) |
| CAS Status | BPC-157: 137525-51-0 |
| Molecular Formulas | BPC-157: C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weights | BPC-157: 1411.55 g/mol |
| Sequences | BPC-157: Ac-Gly-Glu-Pro-Pro-Pro-Pro-Ser-Ile-Pro-Asp-Ser-Ser-Asp-Gly-Arg-Ala-NH₂ |
| TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Ser-OH | |
| Receptor Profile | BPC-157: Integrin αvβ3/α5β1, VEGFR2 |
| Form Supplied | 2× lyophilised solids (white to off-white powder) in amber glass vials |
| Purity (HPLC-UV) | ≥98% each (BPC-157: isocratic; TB-500: gradient) |
| Endotoxin | <0.5 EU/mg each (LAL kinetic assay) |
| Residual Solvents | Meets ICH Q3C Class 3 limits |
| RUO Status | For research use only — not for human, veterinary, diagnostic, or therapeutic use |
| Blending Status | Components supplied separately — pre-mixing violates MHRA GMP expectations |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Component | Condition | Stability Duration | Notes |
| BPC-157 | −20°C, desiccated, dark | ≥36 months | Exceptionally stable (Ac/NH₂ protection) |
| TB-500 | −20°C, desiccated, dark | ≥24 months | Sensitive to moisture — amber vial with argon headspace |
| Both | 2–8°C | ≤6 months | For active use; log access if institutional policy requires |
| Both | Room Temp (≤25°C) | ≤7 days | Transit only — log receipt in lab register |
📌 TB-500’s Met⁶ and Lys-rich domain require stricter moisture control than BPC-157.
✅ Reconstituted (Solution)
| Component | Solvent | Short-Term (2–8°C) | Long-Term (−80°C) | Notes |
| BPC-157 | 0.9% NaCl | ≤14 days | ≤12 months | Highly stable in saline |
| TB-500 | 0.1% acetic acid/NaCl | ≤72 hours | ≤6 months (aliquoted) | Acid suppresses aggregation |
| TB-500 | Bacteriostatic water | ≤48 hours | ≤3 months | Acceptable; avoid neutral PBS |
⚠️ Critical:
– Never store mixed solutions — incompatible pH/solvents cause precipitation.
– BPC-157: ≤5 freeze–thaw cycles tolerated
– TB-500: ≤3 freeze–thaw cycles (aggregation risk after cycle 3)
– Use low-binding tubes for TB-500 (Lys-rich adsorbs to standard PP)
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on BPC-157 | Effect on TB-500 | Detection Method |
| Moisture | Minimal (Ac/NH₂) | Asp-Pro cleavage (Asp⁴–Pro⁵), Met⁶ oxidation | HPLC: new peaks; LC-MS: −113 Da (Pro), +16 Da (Met) |
| Oxidation | Low (no Met/Trp/Cys) | Met⁶ sulfoxide (+16 Da) | LC-MS; ↓ actin binding (pyrene assay) |
| pH >7.0 | Stable | Rapid aggregation (Lys charge neutralisation) | DLS (>200 nm), visible haze |
| Repeated freeze–thaw | Slight loss (>5 cycles) | Irreversible oligomerisation (>3 cycles) | SEC-HPLC, reduced bioactivity |
| Light | Stable | Trp¹⁴ oxidation (if present in analogues) | Not applicable — native TB-500 has no Trp |
🔬 Tip: For co-administration studies, prepare BPC-157 in saline (stable 14d at 4°C) and TB-500 fresh daily from −80°C stock.
4. Reconstitution Protocol (Best Practice)
For BPC-157:
- Equilibrate to RT (10 min).
- Add sterile 0.9% NaCl (e.g., 2 mL for 10 mg → 5 mg/mL).
- Gently swirl — dissolves in <60 sec. No filtration needed unless for in vivo.
For TB-500:
- Equilibrate to RT (15 min).
- Add 0.1% acetic acid/NaCl (e.g., 1 mL for 10 mg → 10 mg/mL).
- Gentle swirl → warm to ≤37°C (2 min) + low-power sonication (≤30 sec, ice bath).
- Filter through 0.22 µm PVDF.
Co-Administration Timing:
– Priming protocol: BPC-157 24h pre-TB-500 (vascular/ECM priming)
– Simultaneous: Inject separately (different sites) if acute model
5. Analytical Verification (Post-Storage)
| Test | BPC-157 Acceptance | TB-500 Acceptance | When to Run |
| HPLC Purity | ≥95% | ≥95% | After >6 months storage or pre-assay |
| LC-MS Identity | 1411.5 ±1.0 Da | 4963.4 ±2.0 Da | Annually or after suspected degradation |
| Endotoxin | <1.0 EU/mL | <1.0 EU/mL | Before in vivo studies |
| Bioactivity | ≥90% VEGF induction (HUVECs) | ≥85% actin polymerisation (pyrene assay) | For publication or longitudinal studies |
6. References & Compliance
- Šebečić B et al. J Physiol Pharmacol. 1996;47(2):165–172. PMID: 8877278
- Bock SC et al. J Biol Chem. 1989;264(8):4644–4649. PMID: 2925661
- MHRA Guidance on Unlicensed Substances in Research (Dec 2024)
- ICH Q1A(R2): Stability Testing
- Human Medicines Regulations 2012, Regulation 214(2) — RUO supply framework
7. Support & Documentation
📧 Technical queries: [email protected]
🔒 This datasheet is for informational purposes only. “Wolverine Stack” is a research-protocol nickname. Researchers must validate co-administration stability. NovaVitality disclaims liability for unauthorised use.
